通过分析呼出气冷凝物鉴定用于潜在肺癌筛查的代谢组学面板。

Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate.

作者信息

Peralbo-Molina A, Calderón-Santiago M, Priego-Capote F, Jurado-Gámez B, Luque de Castro M D

机构信息

Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, University of Córdoba, E-14014, Córdoba, Spain. Institute of Biomedical Research Maimónides (IMIBIC), Reina Sofía Hospital, University of Córdoba, E-14004, Córdoba, Spain.

出版信息

J Breath Res. 2016 Mar 23;10(2):026002. doi: 10.1088/1752-7155/10/2/026002.

DOI:10.1088/1752-7155/10/2/026002

PMID:27007686

Abstract

Exhaled breath condensate (EBC) is one of the less employed biofluids when searching for clinical markers, despite its non-invasive sampling and the potential relationship between its composition and respiratory disease phenotypes such as lung cancer. The advanced stage at which lung cancer is usually detected is the main reason for the high mortality rate of this carcinogenic disease. In this preliminary research, EBC was used as clinical sample to develop a screening tool for lung cancer discrimination from two control groups (with and without risk factor). Three panels of metabolites were configured using the PanelomiX tool to minimize false negatives (specificity) and false positives (sensitivity). The combination of five metabolites led to three panels providing a sensitivity above 77.9%, specificity above 67.5% and the area under the curve (AUC) above 77.5% for the three panels. An additional study was developed as a first approach to study the statistical significance of metabolites at different stages of lung cancer.

摘要

呼出气冷凝物（EBC）在寻找临床标志物时是较少被使用的生物流体之一，尽管其采样无创，且其成分与肺癌等呼吸系统疾病表型之间可能存在关联。肺癌通常在晚期才被检测到，这是这种致癌疾病死亡率高的主要原因。在这项初步研究中，EBC被用作临床样本，以开发一种用于区分肺癌与两个对照组（有和无风险因素）的筛查工具。使用PanelomiX工具配置了三组代谢物，以尽量减少假阴性（特异性）和假阳性（敏感性）。五种代谢物的组合产生了三组，三组的敏感性均高于77.9%，特异性高于67.5%，曲线下面积（AUC）高于77.5%。作为研究肺癌不同阶段代谢物统计学意义的第一步，还开展了一项额外的研究。